Form 4: CONMED Corp: Chief Operating Officer Pat Beyer Reports Stock Option Grant

Pat Beyer, Chief Operating Officer of CONMED Corp, reports the acquisition of 20,060 stock options on April 24, 2024, under the company's 2018 Long-Term Incentive Plan.

Summary

• On April 24, 2024, Pat Beyer, the Chief Operating Officer of CONMED Corp, reported a transaction involving derivative securities.
• Beyer acquired 20,060 options to purchase common stock at a price of $70.01 per share.
• These options were granted under the company's 2018 Long-Term Incentive Plan.
• The options generally vest in equal amounts over a five-year period and expire on April 24, 2034.
• Following the reported transaction, Beyer directly owns 20,060 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding executive compensation. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of stock options to the COO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the medical technology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the medical device industry.
• Companies like Stryker (SYK) and Medtronic (MDT) also utilize stock options as part of their long-term incentive plans for executives.
• The vesting schedule of five years is also fairly standard, encouraging long-term commitment.

Stakeholder Impact

• The stock option grant incentivizes the COO to improve company performance, potentially benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates